ISPE Announces 2013 Board of Directors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE Announces 2013 Board of Directors


ISPE has announced the results of its 2013-2014 International Board of Directors election. The Board will be responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2013 ISPE Annual Meeting, Nov. 3–6 November in Washington, DC.

The following pharmaceutical industry leaders have been elected to positions on the 2013-2014 ISPE International Board of Directors:

Officers
• Chair: Damian Greene, Global Network Strategy Lead, Global Manufacturing and Supply, Zoetis
• Vice Chair: Andy Skibo, Regional Vice President, Biologics-Supply, MedImmune/AstraZeneca
• Treasurer: Joseph Famulare, Vice President – Global Compliance and External Collaboration, Genentech
• Secretary: Mike Arnold, RPh, Business Process Owner for Investigational Products and Senior Director of Strategic Partnerships, Global Clinical Supply Chain, Pfizer
• Past Chair: Charlotte Enghave Fruergaard, PhD, Partner, Global Consulting, NNE Pharmaplan 

Re-elected Directors
• James A. Breen, Jr., PE, LEED AP, Vice President, Worldwide Engineering and Technical Operations, Supply Chain Group, Johnson & Johnson
• Tim Howard, CPIP, PE, Vice President of Global Operations and Company Officer, Commissioning Agents, Inc. 

New Directors
• Mark Fitch, Senior Vice President of Global Operations, Impax Laboratories, Inc.
• Thomas Hartman, Vice President, GMP Operations, Biopharm CMC, GlaxoSmith Kline
• Robert “Bob” Matje, PE, CPIP, Senior Director of Engineering, Endo
• Christopher “Chris” Reid, CEO and Principal Consultant and Owner, Integrity Solutions Ltd.
• Fran Zipp (Sakers), Group Executive Vice President and Head of Quality Operations, Teva

In addition, Jennifer Lauria Clark, CPIP, Jim Durkin, and Gordon Leichter, PhD, who were elected in 2012 to serve a two-year term, will continue as directors.

Source: ISPE

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here